Proliferation profile of classical Hodgkin's lymphomas. Increased expression of the protein cyclin D2 in Hodgkin's and Reed-Sternberg cells

Modern Pathology

Volumn 17, Issue 11, 2004, Pages 1338-1345

  Bai, Maria ^a   Tsanou, Elena ^a   Agnantis, Niki John ^a   Kamina, Sevasti ^a   Grepi, Constantina ^a   Stefanaki, Kalliopi ^b   Rontogianni, Dimitra ^c   Galani, Vassiliki ^a   Kanavaros, Panagiotis ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b Agia Sofia Hospital   (Greece)

^c EVANGELISMOS HOSPITAL   (Greece)

Author keywords

Cell cycle; Hodgkin's lymphomas

Indexed keywords

CYCLIN A; CYCLIN B1; CYCLIN D1; CYCLIN D2; CYCLIN D3; CYCLIN E; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KI 67 ANTIGEN; PROTEIN P16; PROTEIN P27; PROTEIN P53; RETINOBLASTOMA PROTEIN; STAT5A PROTEIN;

ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CORRELATION ANALYSIS; GENE OVEREXPRESSION; GROWTH INHIBITION; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INHIBITION KINETICS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REED STERNBERG CELL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE;

CELL CYCLE; CELL PROLIFERATION; CYCLIN A; CYCLIN B; CYCLINS; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; PROLIFERATING CELL NUCLEAR ANTIGEN; REED-STERNBERG CELLS; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 8144224903     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3800183     Document Type: Article

References (61)

1. Sherr CJ. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 2000;60:3689-3695.
2. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001;1:222-231.
3. Pileri SA, Ascani S, Leoncini L, et al. Hodgkin's lymphoma: the pathologist's viewpoint. J Clin Pathol 2001;55:162-176.
4. Thomas RK, Re D, Wolf J, et al. Part I: Hodgkin's lymphoma-molecular biology of Hodgkin and Reed-Sternberg cells. Lancet Oncol 2004;5:11-18.
5. Erdkamp FL, Schouten HC, Breed WP, et al. DNA aneuploidy in Hodgkin's disease: a multiparameter flow cytometric analysis. Leuk Lymphoma 1994;12:297-306.
6. Weber-Matthiesen K, Deerberg J, Poetsch M, et al. Numerical chromosome aberrations are present within the CD30+ Hodgkin and Reed-Sternberg cells in 100% of analyzed cases of Hodgkin's disease. Blood 1995;86:1464-1468.
7. Leoncini L, Spina D, Close P, et al. Abortive mitoses and nuclear DNA fragmentation, in CD30+ large cells of Hodgkin's disease. Leuk Lymphoma 1995;22:119-124.
8. Spina D, Leoncini L, Close P, et al. Growth vs DNA strand breaks in Hodgkin's disease: impaired proliferative ability of Hodgkin and Reed-Sternberg cells, Int J Cancer 1996;66:179-183.
9. Leoncini L, Spina D, Close P, et al. Mitotic activity and nuclear DNA damage of large cells in Hodgkin's disease: comparison with the expression of p53 and bcl-2 proteins and the presence of Epstein-Barr virus. Leuk Lymphoma 1997;25:153-161.
10. Leoncini L, Spina D, Megha T, et al. Cell kinetics, morphology, and molecular IgVH gene rearrangements in Hodgkin's disease. Leuk Lymphoma 1997;26:307-316.
11. Leoncini L, Megha T, Lazzi S, et al. Cellular kinetic differences between Hodgkin's disease and anaplastic large cell lymphomas: relation to the expression of p34cdc2 and cyclins B1. Int J Cancer 1998;29:408-414.
12. Bargou RC, Emmerich F, Krappmann D, et al. Constitutive nuclear factor-kappnB-ReIA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 1997;100:2961-2969.
13. Hinz M, Loser P, Mathas S, et al. Constitutive NF-kappa B maintains high expression of a characteristic gene network, including CD40, CD86 and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. Blood 2001;97:2798-2807.
14. Izban KF, Ergin M, Huang Q, et al. Characterization of nf-kappab expression in Hodgkin's disease: inhibition of constitutively expressed nf-kappab results in spontaneous caspase-independent apoptosis in Hodgkin and Reed-Sternberg cells. Mod Pathol 2001;14:297-310.
15. Hinz M, Lemke P, Anagnostopoulos I, et al. Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance and link to constitutive signal transducer and activator of transcription 5a activity. J Exp Med 2002;196:605-617.
16. Mathas S, Hinz M, Anagnostopoulos I, et al. Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. EMBO J 2002;21:4104-4113.
17. Sanchez-Beato M, Sanchez-Aguilera A, Piris MA. Cell cycle deregulation in B-cell lymphomas. Blood 2003;101:1220-1235.
18. WAF1/CIP1, wild-type p53-induced proteins, are regularly expressed by Reed-Sternberg cells in Hodgkin's disease. J Pathol 1996;180:58-64.
19. Tzardi M, Kouvidou C, Panagiotides I, et al. Expression of p53 and mdm2 proteins in Hodgkin's disease. Absence of correlation with the presence of Epstein-Barr virus. Anticancer Res 1996;16:2813-2820.
20. Lorenzen J, Thile J, Fischer R. The mummified Hodgkin cell: cell death in Hodgkin's disease. J Pathol 1997;182:288-298.
21. Morente MM, Piris MA, Abraira V, et al. Adverse clinical outcome in Hodgkin's disease is associated with loss of retinoblastoma protein expression high Ki67 proliferation index and absence of Epstein-Barr virus latent membrane protein 1 expression. Blood 1997;80:2429-2436.
22. Naresh KN, O'Connor G, Soman C, et al. A study of p53 protein, proliferation cell nuclear antigen and p21 in Hodgkin's disease at presentation and at relapse. Hum Pathol 1997;28:549-555.
23. Brink AA, Oudejans JJ, van den Brule AJ, et al. Low p53 and high bcl2 expression in Reed-Sternberg cells predicts poor clinical outcome for Hodgkin's disease: involvement in apoptosis resistance. Mod Pathol 1998;11:376-383.
24. Garcia JF, Villuendas R, Algara P, et al. Loss of p16 protein expression associated with methylation of the p16INK4A gene is a frequent finding in Hodgkin's disease. Lab Invest 1999;79:1453-1459.
25. Guenova M, Rassidakis GZ, Gorgoulis VG, et al. p16/INK4A is regularly expressed in Hodgkin's disease: comparison with retinoblastoma, p53 and MDM2 protein status, and the presence of Epstein-Barr Virus. Mod Pathol 1999;12:1062-1071.
26. Ohshima K, Haraoka S, Fujiki T, et al. Expressions of cyclin E, A, and B1 in Hodgkin and Reed-Sternberg cells: not suppressed by cyclin-dependent kinase inhibitor p21 expression. Pathol Int 1999;49:506-512.
27. Lauritzen AF, Moller PH, Nedergaard T, et al. Apoptosis related genes and proteins in Hodgkin's disease. APMIS 1999;107:636-644.
28. Kanavaros P, Stefanaki K, Vlachonikolis J, et al. Expression of p53, p21/waf-1, bcl-2, bax, Rb and Ki-67 proteins in Hodgkin's lymphomas. Histol Histopathol 2000;15:445-453.
29. Kolar Z, Flavell JR, Ehrman J, et al, Apoptosis in malignant cells in Hodgkin's disase is related to expression of the cdk inhibitor p27KIP1. J Pathol 2000;190:604-612.
30. Garcia JF, Villuendas R, Sanchez-Beato M, et al. Nucleolar p14 (ARF) overexpression in Reed-Sternberg cells in Hodgkin's lymphoma: absence of p14 (ARF)/Hdm2 complexes is associated with expression of alternatively spliced Hdm2 transcripts. Am J Pathol 2002;160:569-578.
31. Garcia MJ, Martinez-Delgado B, Cebrian A, et al. Different incidence and pattern of p15INK4b and p16INK4a promoter region hypermethylation in Hodgkin's and CD30-positive non-Hodgkin's lymphomas. Am J Pathol 2002;161:1007-1013.
32. Sanchez-Aguilera A, Delgado J, Camacho FI, et al. Silencing of the p18INK4c gene by promoter hypermethylation in Reed-Sternberg cells in Hodgkin lymphomas. Blood [prepublished online 2003-07-2356].
33. Garcia JF, Camacho FI, Morente M, et al. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood 2003;101:681-689.
34. Devilard E, Bertucci F, Trempat P, et al. Gene expression profiling defines molecular subtypes of classical Hodgkin's disease. Oncogene 2002;21:3095-3102.
35. Doglioni C, Chiarelli C, Macri E, et al. Cyclin D3 expression in normal, reactive and neoplastic tissues. J Pathol 1998;185:159-166.
36. Teramoto N, Pokrovskaja K, Szekely L, et al. Expression of cyclin D2 and D3 in lymphoid lesions. Int J Cancer 1999;81:543-550.
37. Tzankov A, Zimpfer A, Lugli A, et al. High-throughput tissue microarray analysis of G1-cyclin alterations in classical Hodgkin's lymphoma indicates overexpression of cyclin E1. J Pathol 2003;199:201-207.
38. Sanchez-Beato M, Camacho FI, Martinez-Montero JC, et al. Anomalous high p27/KIP1 expression in a subset of aggressive B-cell lymphomas is associated with cyclin D3 overexpression and P27/KIP1-cyclin D3 colocalization in tumor cells. Blood 1999;94:765-772.
39. Bai M, Vlachonikolis J, Agnantis NJ, et al. Low expression of p27 protein combined with altered p53 and Rb/p16 expression status is associated with increased expression of cyclin A and cyclin B1 in diffuse large B-cell lymphomas. Mod Pathol 2001;14:1105-1113.
40. Bai M, Tsanou E, Agnantis NJ, et al. Expression of cyclin D3 and cyclin E and identification of distinct clusters of proliferative activity and apoptosis status in diffuse large B-cell lymphomas. Histol Histopathol 2003;18:449-457.
41. Harris NL. Hodgkin's disease: classification and differential diagnosis. Mod Pathol 1999;12:159-175.
42. Stein H, Delsol G, Pileri S. Classical Hodgkin's lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Haematopoietic and Lymphoid Tissues. Lyon, International Agency for Research on Cancer (IARC) Press, 2001, pp 244-253.
43. Suzuki R, Kuroda H, Komatsu H, et al. Selective usage of D-type cyclins in lymphoid malignancies. Leukemia 1999;13:1335-1342.
44. Camacho FI, Garcia JF, Sanchez-Verde L, et al. Unique phenotypic profile of monocytoid B-cells: differences in comparison with the phenotypic profile observed in marginal zone B-cells and so-called monocytoid B cell lymphoma. Am J Pathol 2001;158:1363-1369.
45. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2003;103:275-282.
46. Delmer A, Ajchenbaum-Cymbalista F, Tang R, et al. Overexpression of cyclin D2 in chronic B-cell malignancies. Blood 1995;85:2870-2876.
47. Martino A, Holmes JH, Lord JD, et al. Stat5 and Sp1 regulate transcription of the cyclin D2 gene in response to IL-2. J Immunol 2001;166:1723-1729.
48. Brooks AR, Shiffman D, Chan CS, et al. Functional analysis of the human cyclin D2 and cyclin D3 promoters. J Biol Chem 1996;271:9090-9099.
49. Spruck CH, Won KA, Reed SI. Deregulated cyclin E induces chromosome instability. Nature 1999;401:297-300.
50. D'Angiolella V, Costanzo V, Gottesman ME, et al. Role for cyclin-dependent kinase 2 in mitosis exit. Curr Biol 2001;11:1221-1226.
51. Ott M, Bartkova J, Bartek J, et al. Cyclin D1 expression in mantle cell lymphoma is accompanied by down-regulation of cyclin D3 and is not related to the proliferative activity. Blood 1997;90:3154-3159.
52. Lam EWF, Glassford J, Banerji L, et al. Cyclin D3 compensates for loss of cyclin D2 in mouse B-lymphocytes activated via the antigen receptor and CD40. J Biol Chem 2000;275:3479-3484.
53. Bartek J, Lukas J. Pathways governing the G1/S transition and their response to DNA damage. FEBS Lett 2000;490:117-122.
54. Den Eltzen N, Pines J. Cyclin A is destroyed in prometaphase and can delay chromosome alignment and anaphase. J Cell Biol 2001;153:121-136.
55. Smits V, Medema R. Checking out the G2/M transition. Biochem Biophys Acta 2001;1519:1-12.
56. Abele MC, Valente G, Kerim S, et al. Significance of cell proliferation index in assessing histological prognostic categories in Hodgkin's disease. An immunohistochemical study with Ki67 cind MIB-1 monoclonal antibodies. Haematologica 1997;82:281-285.
57. Taylor WR, Deprimo SE, Agarwal A, et al. Mechanisms of G2 arrest in response to overoxpression of p53. Mol Biol Cell 1999;10:3607-3622.
58. Innocente SA, Abrahamson JLA: Cogswell JP, et al. P53 regulates a G2 checkpoint through cyclin B1. Proc Natl Acad Sci USA 1999;96:2147-2152.
59. Zerfass-Thome K, Schultze A, Zwerschkew W, et al. P27/KIP1 blocks cyclin E-dependent transactivation of cyclin A gene expression. Mol Cell Biol 1997;17:407-415.
60. Lin Z, Lim S, Lim MS. Growth regulation by p27/Kip1 is abrogated by multiple mechanisms in aggressive malignant lymphomas. Br J Haematol 2003;121:739-748.
61. Philipp-Staheli J, Payne SR, Kemp CJ. p27(Kip1): regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. Exp Cell Res 2001;264:148-168.